POINT-Logo-Colour (1).png
POINT Biopharma to Participate in Upcoming Investor Conferences
May 19, 2022 17:30 ET | POINT Biopharma
INDIANAPOLIS, May 19, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
Inspirata Joins Advarra’s New API Partner Program as an Inaugural Member
May 18, 2022 09:00 ET | Inspirata, Inc.
Tampa, Florida, May 18, 2022 (GLOBE NEWSWIRE) -- Cancer informatics provider Inspirata announced today that it has become a member of the Advarra Partner Program. As an inaugural API Gold partner,...
YSEOP_LOGO_FINAL-PURPLE-_-YELLOW (1).png
Yseop’s AI-Powered Augmented Analyst Chosen by Lilly to Expedite the Drug Approval Process and Deploy Automation at Scale
May 18, 2022 08:00 ET | Yseop
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Yseop, a world-leading AI software company and pioneer in Natural Language Processing (NLP), today announced a strategic collaboration with Eli Lilly and...
Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
May 18, 2022 07:00 ET | https://immatics.com/
The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint...
Immatics behandelt ersten Patienten mit ACTengine® TCR-T-Zelltherapie IMA203 in Kombination mit Checkpoint-Inhibitor Opdivo® (Nivolumab) in Patienten mit fortgeschrittenen soliden Tumoren
May 18, 2022 07:00 ET | Immatics N.V.
Die Phase-1b-Dosis-Expansionskohorte untersucht die Sicherheit, biologische Aktivität und erste Anzeichen einer Anti-Tumor-Aktivität der IMA203 TCR-T-Zelltherapie gegen die Zielstruktur PRAME in...
POINT-Logo-Colour (1).png
POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
May 16, 2022 08:30 ET | POINT Biopharma
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy INDIANAPOLIS,...
POINT-Logo-Colour (1).png
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
May 13, 2022 08:30 ET | POINT Biopharma
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada...
22157.jpg
2022 Clinical Trials Analysis Report: Clinical Trials Planned to Initiate in 2022, Clinical Trials Estimated to Complete in 2022, Spotlight on COVID-19 Clinical Trials
May 13, 2022 06:58 ET | Research and Markets
Dublin, May 13, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trials in 2022 - A Preview of Trials Planned to Initiate and Estimated to Complete in 2022" report has been added to ResearchAndMarkets.com's...
Picture1.jpg
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
May 12, 2022 01:05 ET | Curium
ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium...
Medi Tech Insights Logo.jpg
Global Clinical Trial Supplies Market valued at $2.5 billion in 2021, is expected to grow at a decent CAGR of 8%
May 10, 2022 10:50 ET | Medi-Tech Insights
BRUSSELS, Belgium, May 10, 2022 (GLOBE NEWSWIRE) -- Description: The clinical trial supplies (CTS) market includes services like packaging and labeling services, clinical supplies logistics &...